Terminated PHASE3 INTERVENTIONAL 2-arm NCT01359813

Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis (ALB-CIRINF)

Effects of Albumin Administration in Septic Cirrhotic Patients With Child > 8 Unrelated to Spontaneous Bacterial Peritonitis on Renal Function and Survival: A Multicenter Randomized Controlled Trial Comparing Use and Non-use of Human Albumin (Vialebex ®)

Sponsor: Centre Hospitalier Universitaire de Besancon

Conditions Cirrhosis Renal Failure Sepsis

Interventions Human Albumin

Updated 10 times since 2017 Last updated: May 12, 2014 Started: Dec 31, 2008 Primary completion: Sep 30, 2011 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

decision of independent monitoring committee:Risk of death at 3 months higher in Albumin group than in control group, without reaching significance level.

Other terminated trials from Centre Hospitalier Universitaire de Besancon

See all terminations from Centre Hospitalier Universitaire de Besancon

Other Cirrhosis trials with similar outcome

Browse all Cirrhosis trials

This PHASE3 trial investigates Cirrhosis and Renal Failure and is currently terminated or withdrawn. Centre Hospitalier Universitaire de Besancon leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire de Besancon
Ministry of Health, France

Data source: Centre Hospitalier Universitaire de Besancon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Angers, France , Belfort, France , Besançon, France , Bondy, France , Bordeaux, France , Brest, France , Caen, France , Clamart, France , Clermont-Ferrand, France and 23 more locations